Resources Repository
-
ReviewPublication 2010Validation of Population-Based Disease Simulation Models: A Review
This article develops a framework for validating population-based chronic disease simulation models, and reviews the …
This article develops a framework for validating population-based chronic disease simulation models, and reviews the principles and methods for such models. While computer simulation models are used increasingly to support public health research and policy, questions about their quality persist. Based on the review, the authors formulated a set of recommendations for gathering evidence of model credibility. They find that evidence of model credibility derives from examining: 1) the process of model development, 2) the…
Mathematical Models | Calibration/Validation | Chronic Disease/Risk | Social Determinants | Health/Medicine -
ReviewPublication 2006Ethical Issues in Resource Allocation, Research, and New Product Development
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care …
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care are most acute when needs are great and resources few. This chapter from the Disease Control Priorities in Developing Countries 2nd edition addresses some of these concerns, identifying some of the principal ethical issues that arise in the development and allocation of effective interventions for developing countries and discussing some alternative resolutions. Resource allocation in health and elsewhere should satisfy two main…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Preferences/Values | Culture/Society | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Mathematical Models | Cost-Effectiveness Analysis | Decision Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America -
ReviewPublication 2018Equity Considerations in CEA: Rotavirus Vaccine in LMIC's
The authors used a systematic review of the literature to identify economic evaluations of rotavirus …
The authors used a systematic review of the literature to identify economic evaluations of rotavirus vaccine in LMICs and assess the extent to which equity was considered in the objectives, analysis, and results. They used equity-related indicators provided in the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria resulting in 18 unique indicators tracked. The authors found that some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented…
Cost-Effectiveness Analysis | Evidence Synthesis | Infectious Diseases | Social Determinants | Health/Medicine | Global -
ReviewPublication 2018Setting Health Sector Priorities: A Brief Overview of Ethiopia's Experience
Based on Ethiopia’s commitment to attain universal health coverage by 2035, the authors use the …
Based on Ethiopia’s commitment to attain universal health coverage by 2035, the authors use the current national strategies including the national essential health service package in Ethiopia as a springboard to explore the criteria and processes Ethiopia uses to set the existing national health sector priorities. Addition the authors highlight the critical need to strengthen country-led efforts and investments in human capital in developing country contexts.
Priority Setting/Ethics | Evidence Synthesis | Health Systems | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
ReviewPublication 2018Incorporating MCDA into HTA: A Focus on Lower Income Settings
The authors present key challenges, both methodological and practical against using multicriteria decision analysis (MCDA) …
The authors present key challenges, both methodological and practical against using multicriteria decision analysis (MCDA) in health technology assessment (HTA) as well as solutions to these challenges. They showcase lessons learned from previous applications of MCDS to HTA, including design, criteria of models, approaches for estimating costs and challenges with various approaches. By showing efforts that have succeeded in overcoming these challenges in lower and middle income-countries, they show how MCDA has the potential to…
Priority Setting/Ethics | Health Systems | Health/Medicine | Global